MeiraGTx Holdings plc entered into Collaboration Agreement with Hologen Neuro AI UK Limited and Hologen Limited and Hologen Neuro AI Limited (effective 2026-04-20).
“the Company, MeiraGTx Neuro UK, MeiraGTx Neuro I, LLC, a Delaware limited liability company (“MeiraGTx Neuro US”), Hologen, HNAI and Hologen Neuro AI UK Limited, a private company limited by shares incorporated in England (“HNAI UK”), entered into the Collaboration and License Agreement (the “Collaboration Agreement”), for the research, development, manufacture and commercialization of the Company’s (i) AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for the treatment of genetic obesity disorders and other potential locally delivered genetic medicines to the central nervous system (the “Clinical Programs”) and (ii) proprietary device designed to effect the local delivery of a gene therapy product into the central nervous system or any topographic or subcutaneous tissue modification on the face and scalp, of humans or animals (the “Delivery Device”), in each case, in accordance with the terms and conditions of the Coll”
Material Agreements
MeiraGTx Holdings plc terminated Original Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. (effective 2026-04-15).
“Seller and Buyer entered into a Termination Agreement on April 15, 2026 (the “Termination Agreement”) terminating that certain Asset Purchase Agreement, dated as of December 20, 2023 (the “Original Asset Purchase Agreement”), by and among Seller and the Company and its wholly-owned subsidiary MeiraGTx UK II Limited, a company incorporated in England and Wales (“MeiraGTx UK II”), that certain Supply Agreement, dated as of December 20, 2023 by and between MeiraGTx UK II and Seller, and certain other documents related to the Original Asset Purchase Agreement.”
Material Agreements
MeiraGTx Holdings plc entered into Asset Purchase Agreement with Janssen Pharmaceuticals, Inc. valued at $25,000,000 (effective 2026-04-15).
“On April 15, 2026 (the “Closing Date”), MeiraGTx Holdings plc (the “Company”) and its wholly-owned subsidiary MeiraGTx Ocular UK Limited, a company incorporated in England and Wales (“MeiraGTx Ocular” and together with the Company, collectively the “Buyer”), entered into and consummated an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“Seller”), pursuant to which Seller sold and assigned to Buyer, and Buyer purchased and assumed, that certain License Agreement, dated February 5, 2019, by and between UCL Business Plc (now UCL Business Ltd.) and Janssen (the “UCL License Agreement”), relating to the research, development, manufacture and exploitation of Seller’s gene therapy product for the treatment of X-linked retinitis pigmentosa related to mutations in the RPGR gene (the “RPGR Product”), and other related assets as described in the Asset Purchase Agreement. Buyer agreed to pay an upfront cash purchase price o”
Material Agreements
MeiraGTx Holdings plc entered into Underwriting Agreement with BofA Securities, Inc. and Goldman Sachs & Co. LLC valued at approximately $93.3 million (effective 2026-04-16).
“On April 16, 2026, MeiraGTx Holdings plc (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc. and Goldman Sachs & Co. LLC (the “Underwriters”), in connection with the issuance and sale by the Company in an offering of 11,111,111 ordinary shares of the Company (the “Shares”) at an offering price of $9.00 per share, less underwriting discounts and commissions”
M&A Transactions
MeiraGTx Holdings plc completed an acquisition involving Janssen Pharmaceuticals, Inc. for upfront cash purchase price of $25,000,000 (closed 2026-04-15).
“to mutations in the RPGR gene (the “RPGR Product”), and other related assets as described in the Asset Purchase Agreement. Buyer agreed to pay an upfront cash purchase price of $25,000,000 to Seller. Additionally, pursuant to and subject to the terms and conditions set forth in the Asset Purchase Agreement, Buyer agreed to pay Seller a one-time, future contingent”
Earnings Releases
MeiraGTx Holdings plc reported financial results for the year ended December 31, 2025.
“On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.”
Debt Financings
MeiraGTx Holdings plc amended senior notes with Perceptive Credit Holdings III, LP maturing May 2, 2027.
“Under the Amendments, the Maturity Date (as defined under the Notes Purchase Agreement) has been extended from August 2, 2026 to May 2, 2027 and the Company has agreed to redeem a portion of the outstanding principal amount of the Notes (as defined under the Notes Purchase Agreement) equal to $25,000,000 on or before June 30, 2026.”
Material Agreements
MeiraGTx Holdings plc amended Amendment No. 4 to Amended and Restated Notes Purchase Agreement and Amendment No. 1 to Warrant Certificates with Perceptive Credit Holdings III, LP valued at Extended Maturity Date from August 2, 2026 to May 2, 2027; agreed to redeem $25,000,000 principal on (effective 2026-03-25).
“Item 1.01. Entry Into a Material Definitive Agreement. On March 25, 2026, MeiraGTx Holdings plc (the “Company”), as issuer, and its wholly-owned subsidiaries MeiraGTx UK II Limited, a company incorporated in England and Wales (“MeiraGTx UK II”), and MeiraGTx Ireland DAC, a designated activity company limited by shares incorporated in Ireland (“MeiraGTx Ireland,” and together with MeiraGTx UK II, the “Subsidiary Guarantors”), the noteholders and other parties from time to time party to the Notes Purchase Agreement (as defined below), and Perceptive Credit Holdings III, LP, as administrative agent and noteholder under the Notes Purchase Agreement (“Perceptive”), entered into Amendment No. 4 to Amended and Restated Notes Purchase Agreement and Amendment No. 1 to Warrant Certificates (the “Amendments”). The Amendments amend (A) the Amended and Restated Notes Purchase Agreement and Guaranty, dated December 19, 2022, between the Company, the Subsidiary Guarantors, the noteholders and oth”
Material Agreements
MeiraGTx Holdings plc entered into Share Purchase Agreement with Perceptive Life Sciences Master Fund, Ltd. valued at $18,193,000 (effective 2025-12-31).
“On December 31, 2025, MeiraGTx Holdings plc (the “Company”) entered into a share purchase agreement (the “Share Purchase Agreement”) with Perceptive Life Sciences Master Fund, Ltd. (“Perceptive Master Fund”), an affiliate of Perceptive Advisors LLC (“Perceptive Advisors”), pursuant to which the Company agreed to purchase 2,300,000 of the Company’s ordinary shares, $0.00003881 par value per share (the “Ordinary Shares”), from Perceptive Master Fund at a price of $7.91 per share (which was the volume-weighted average price (VWAP) per share on the Nasdaq Global Select Market on December 31, 2025), for an aggregate purchase price of $18,193,000 (the “Share Repurchase”).”
Earnings Releases
MeiraGTx Holdings plc reported financial results for the first quarter ended March 31, 2024.
“On May 9, 2024, MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Earnings Releases
MeiraGTx Holdings plc reported financial results for the fourth quarter and full-year ended December 31, 2023.
“On March 14, 2024, MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.